Innovation is the translation of a new method, idea, or product into reality and profit. It is a process of connected steps that accumulates into your brand or reputation. However, there can be many pitfalls and wrong turns on the road to realizing this goal. Innovation, Commercialization, and Start-Ups in Life Sciences details the methodologies necessary to create a successful life sciences start-up from initiation to exit. You will gain an appreciation for the necessary data, partnership, and skills to be acquired and the constituencies that must be satisfied along the way. The book examines how life sciences start-ups can create an exit for their investors by recognizing that a liquidity event is not consummated without due diligence. Due diligence is bigger than validating accounting transactions. It ensures the company is solving an important customer problem, demonstrating sales access, and making sure that intellectual property is impervious to competitive advancement. The due diligence process supports the telling of a compelling story to customers, investors, regulators, and acquirers. Written by an expert who has worked with more than 200 life sciences start-ups during the past decade, the book discusses specific processes and investor milestones that must be navigated to align customer, funder, and acquirer needs. It examines these processes from the perspective of marketing value through a focus on the needs of individual constituents-investors, regulators, customers, and exit candidates. The book presents data and analytical processes articulating the fundable milestones for angel and venture capital. It gives you the tools needed to create branding for public investors and more.

Focused specifically on Life Science Start-Ups Examines how to determine a company valuation and future "fundable milestones" Explores how to align regulatory and clinical strategies Discusses intellectual property derived from a university or individual through formation to exit. Reviews how start-ups must simultaneously meet the needs of multiple constituencies at once: investors, regulators, customers and exit candidates

Focused specifically on Life Science Start-Ups Examines how to determine a company valuation and future "fundable milestones" Explores how to align regulatory and clinical strategies Discusses intellectual property derived from a university or individual through formation to exit. Reviews how start-ups must simultaneously meet the needs of multiple constituencies at once: investors, regulators, customers and exit candidates

Vietnam was called (The Jewel of the Orient )that's all I knew about that small little country in Southeast Asia. This is the story about a guy who grew up in the streets of Philadelphia who enlisted into the Marine corps and ended up in the rice patties outside Danang. I will try to explain what I saw and how I felt from the day I landed until the day I departed Thirteen months later. I will do my best to make plain and clear what it felt like to be placed into an infantry unit where I had to adapt to my new surroundings. I'll tell you my feelings, being accepted into a squad of experienced grunts. Guys that I would spend every day and night with, Guys who cared for each other and watched each others back, we were brothers and we knew it. All we had was each other and every time we went out on patrol, we knew that it was up to us to survive together. I participated in over 250 patrols and ambushes and 5 Operations and I can honestly tell you that I served my tour of duty with the greatest group of guys anyone could ever serve with. We were members of the 2'nd Battalion 1'st Marine Division (The Professionals) the North Vietnamese Army referred to us as The Ghost Battalion.